



NDA 50-662/S-056
NDA 50-698/S-036
NDA 50-775/S-024

SUPPLEMENT APPROVAL

Abbvie, Inc.
Attention: Kelly Kaleck-Schlinsog, M.S.
Associate Director, Regulatory Affairs – US & Canada
1 North Waukegan Road
North Chicago, IL 60064

Dear Ms. Kaleck-Schlinsog:

Please refer to your Supplemental New Drug Applications (sNDAs) dated May 9, 2014, received May 9, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Drug Name	NDA #/Supplement
Biaxin Filmtabs (clarithromycin tablets, USP)	NDA 50-662/S-056
Biaxin Granules (clarithromycin for oral suspension USP)	NDA 50-698/S-036
Biaxin XL Filmtabs (clarithromycin extended release tablets)	NDA 50-775/S-024

We acknowledge receipt of your amendment dated December 8, 2014.

These “Prior Approval” supplemental new drug applications propose to add acute kidney injury with concomitant use of calcium channel blockers metabolized by CYP3A4 to the **Drug Interactions** subsection of the **WARNINGS** and **Geriatric Use** sections of the labeling.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your December 8, 2014, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 50-662/S-056
NDA 50-698/S-036
NDA 50-775/S-024

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
01/08/2015